Suppr超能文献

实验性流感病毒攻击的有症状和无症状反应中外周细胞因子水平的差异演变。

Differential evolution of peripheral cytokine levels in symptomatic and asymptomatic responses to experimental influenza virus challenge.

作者信息

McClain M T, Henao R, Williams J, Nicholson B, Veldman T, Hudson L, Tsalik E L, Lambkin-Williams R, Gilbert A, Mann A, Ginsburg G S, Woods C W

机构信息

Center for Applied Genomics and Precision Medicine, Duke University, Durham, NC, USA.

Durham Veterans Affairs Medical Center, Durham, NC, USA.

出版信息

Clin Exp Immunol. 2016 Mar;183(3):441-51. doi: 10.1111/cei.12736. Epub 2015 Dec 16.

Abstract

Exposure to influenza virus triggers a complex cascade of events in the human host. In order to understand more clearly the evolution of this intricate response over time, human volunteers were inoculated with influenza A/Wisconsin/67/2005 (H3N2), and then had serial peripheral blood samples drawn and tested for the presence of 25 major human cytokines. Nine of 17 (53%) inoculated subjects developed symptomatic influenza infection. Individuals who will go on to become symptomatic demonstrate increased circulating levels of interleukin (IL)-6, IL-8, IL-15, monocyte chemotactic protein (MCP)-1 and interferon (IFN) gamma-induced protein (IP)-10 as early as 12-29 h post-inoculation (during the presymptomatic phase), whereas challenged patients who remain asymptomatic do not. Overall, the immunological pathways of leucocyte recruitment, Toll-like receptor (TLR)-signalling, innate anti-viral immunity and fever production are all over-represented in symptomatic individuals very early in disease, but are also dynamic and evolve continuously over time. Comparison with simultaneous peripheral blood genomics demonstrates that some inflammatory mediators (MCP-1, IP-10, IL-15) are being expressed actively in circulating cells, while others (IL-6, IL-8, IFN-α and IFN-γ) are probable effectors produced locally at the site of infection. Interestingly, asymptomatic exposed subjects are not quiescent either immunologically or genomically, but instead exhibit early and persistent down-regulation of important inflammatory mediators in the periphery. The host inflammatory response to influenza infection is variable but robust, and evolves over time. These results offer critical insight into pathways driving influenza-related symptomatology and offer the potential to contribute to early detection and differentiation of infected hosts.

摘要

接触流感病毒会在人类宿主中引发一系列复杂的事件。为了更清楚地了解这种复杂反应随时间的演变,人类志愿者接种了甲型/威斯康星/67/2005(H3N2)流感病毒,然后采集系列外周血样本,并检测25种主要人类细胞因子的存在情况。17名接种受试者中有9名(53%)发生了有症状的流感感染。那些将出现症状的个体早在接种后12 - 29小时(在症状前期)就表现出循环中的白细胞介素(IL)-6、IL-8、IL-15、单核细胞趋化蛋白(MCP)-1和干扰素(IFN)γ诱导蛋白(IP)-10水平升高,而未出现症状的受挑战患者则没有。总体而言,白细胞募集、Toll样受体(TLR)信号传导、先天性抗病毒免疫和发热产生的免疫途径在疾病早期有症状个体中均过度呈现,但也是动态的且随时间不断演变。与同时期外周血基因组学的比较表明,一些炎症介质(MCP-1、IP-10、IL-15)在循环细胞中活跃表达,而其他一些(IL-6、IL-8、IFN-α和IFN-γ)可能是在感染部位局部产生的效应物。有趣的是,无症状的接触者在免疫和基因组方面也并非静止不动,而是在外周表现出重要炎症介质的早期和持续下调。宿主对流感感染的炎症反应是可变但强烈的,并且随时间演变。这些结果为驱动流感相关症状的途径提供了关键见解,并为感染宿主的早期检测和鉴别提供了潜在帮助。

相似文献

5
Differences in serum cytokine levels between influenza virus A and B infections in children.
Cytokine. 2009 Jul;47(1):65-8. doi: 10.1016/j.cyto.2009.05.003. Epub 2009 Jun 3.
6
8
Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza.
J Infect Dis. 2015 Apr 1;211(7):1038-44. doi: 10.1093/infdis/jiu539. Epub 2014 Oct 3.
9
Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats.
Antiviral Res. 2007 Jan;73(1):1-11. doi: 10.1016/j.antiviral.2006.07.011. Epub 2006 Aug 18.

引用本文的文献

6
Controlled Human Infection Models To Accelerate Vaccine Development.
Clin Microbiol Rev. 2022 Sep 21;35(3):e0000821. doi: 10.1128/cmr.00008-21. Epub 2022 Jul 6.
7
Pandemics of the 21st Century: The Risk Factor for Obese People.
Viruses. 2021 Dec 23;14(1):25. doi: 10.3390/v14010025.
8
Nonrespiratory sites of influenza-associated disease: mechanisms and experimental systems for continued study.
FEBS J. 2022 Jul;289(14):4038-4060. doi: 10.1111/febs.16363. Epub 2022 Feb 7.
9
The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?
Cytokine. 2021 Aug;144:155593. doi: 10.1016/j.cyto.2021.155593. Epub 2021 May 26.
10
GPER1 is required to protect fetal health from maternal inflammation.
Science. 2021 Jan 15;371(6526):271-276. doi: 10.1126/science.aba9001.

本文引用的文献

3
Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection.
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):769-74. doi: 10.1073/pnas.1321748111. Epub 2013 Dec 23.
4
Cellular immune correlates of protection against symptomatic pandemic influenza.
Nat Med. 2013 Oct;19(10):1305-12. doi: 10.1038/nm.3350. Epub 2013 Sep 22.
5
Cytokine and chemokine levels in patients infected with the novel avian influenza A (H7N9) virus in China.
J Infect Dis. 2013 Dec 15;208(12):1962-7. doi: 10.1093/infdis/jit440. Epub 2013 Aug 29.
6
Cytokine responses in patients with mild or severe influenza A(H1N1)pdm09.
J Clin Virol. 2013 Sep;58(1):100-7. doi: 10.1016/j.jcv.2013.05.011. Epub 2013 Jun 20.
7
The TLR4 antagonist Eritoran protects mice from lethal influenza infection.
Nature. 2013 May 23;497(7450):498-502. doi: 10.1038/nature12118. Epub 2013 May 1.
9
10
Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection.
Antiviral Res. 2012 Dec;96(3):391-404. doi: 10.1016/j.antiviral.2012.09.013. Epub 2012 Sep 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验